A study of DS109 for the treatment of inflammatory skin disorders.
Phase of Trial: Phase I
Latest Information Update: 06 Jan 2017
At a glance
- Drugs Dihomo-gamma linolenic acid (Primary)
- Indications Skin disorders
- Focus Adverse reactions
- 06 Jan 2017 Status changed from planning to completed, as per a DS Biopharma media release.
- 02 Oct 2016 New trial record
- 14 Sep 2016 According to a DS Biopharma media release, the company anticipates to begin this study later in 2016.